Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GALR2 | O43603 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287081 | 0.85 | BCL2 (0.49) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL1287142 | 0.83 | RAB9A (0.50) | MEN1RAB9AKMT2AMAPTMAPK1 | |
| SCHEMBL1287130 | 0.83 | BCL2 (0.48) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL1287135 | 0.81 | IDO1 (0.59) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL1287085 | 0.80 | DHODH (0.47) | MAPTBCL2TP53IDO1TDO2 | |
| SCHEMBL10220599 | 0.76 | IDO1 (0.51) | MEN1RAB9AKMT2AMAPTMAPK1 | |
| SCHEMBL15303396 | 0.73 | CHEK1 (0.48) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL5725681 | 0.72 | CDK5 (0.48) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL6135662 | 0.71 | MAPT (0.40) | MEN1RAB9AKMT2AMAPTGAA | |
| SCHEMBL5025816 | 0.70 | RAB9A (0.70) | MEN1RAB9AKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040713-B2 | Methods of managing blood sugar levels and compositions related thereto | EMORY UNIVERSITY (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012047628-A2 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158082-A1 | METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO | SLC5A1, SLC2A1, SLC5A2 | MEN1 1416/4885RAB9A 1411/4885KMT2A 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.